News from Hyrax Biosciences

Recent articles

Exatype Continues to Facilitate COVID-19 Monitoring as Winter Flu Season Hits South Africa

Dr Natasha Wood 08/07/2024

As South Africa enters the winter season, the country is experiencing a small uptick in COVID-19 cases amidst the concurrent flu season. The latest data indicates that the total number of confirmed COVID-19 cases has reached over 4 million, with more than 102 000 deaths reported since the pandemic began. Hyrax Biosciences remains committed to supporting SARS-CoV-2 variant detection and surveillance through Exatype, its online analysis platform.

Read full article

Hyrax Biosciences launch Exatype Mtb!

Dr Natasha Wood 08/05/2024

To support the analysis of Mtb data using NGS technologies, Hyrax Biosciences recently launched Exatype Mtb for targeted and whole-genome sequencing (WGS). Incorporating the latest WHO mutation catalogue, Exatype Mtb generates comprehensive drug-susceptibility reports and lineage-typing results. True to the streamlined nature of the Exatype platform, Exatype Mtb offers a secure, cloud-based, high-throughput solution for NGS-based Mtb drug-susceptibility reporting.

Read full article

Hyrax Biosciences to include HIV, TB, and respiratory virus panels in their co-marketing agreement with Roche

Dr Natasha Wood 29/04/2024

Hyrax Biosciences is extending their co-marketing agreement with Roche to include integrated sample preparation workflows for HIV, TB and respiratory virus panels. With Hyrax Biosciences' streamlined analysis and Roche's KAPA HyperCap and KAPA HyperPETE workflows for Next Generation Sequencing (NGS) Sample Preparation, users can expect faster turn-around times, sequencing efficiency, and panel-specific consolidated reporting.

Read full article

Will we see an end to the acute phase of the COVID-19 pandemic in 2022?

Dr Natasha Wood 01/04/2022

On Wednesday (30 March 2022), the WHO released an updated, and the third version, of their Strategic Preparedness, Readiness and Response Plan for COVID-19. During his opening remarks at the press conference, WHO Director General, Dr Tedros Adhanom Ghebreyesus, emphasised the importance of equitable vaccination and continued surveillance – not only in response to COVID-19, but also for future epidemics.

Read full article

SARS-CoV-2 sequence analysis software in simple terms.

Dr Natasha Wood 23/03/2022

SARS-CoV-2 sequence analysis software are NGS tools for analysing and interpreting the DNA of the coronavirus that caused the COVID-19 pandemic. There are multiple steps in the analysis workflow, and at each step, a researcher or laboratory scientist can use an array of different SARS-CoV-2 sequence analysis software to obtain the results they need.

Read full article

The power of NGS tools to decipher DNA.

Dr Natasha Wood 10/03/2022

Next-generation sequencing (NGS) is a catch-all phrase for all the sequencing technologies that share the approach of using massively parallel processing. Compared to first-generation sequencing (commonly referred to as Sanger sequencing) that produces a single read (DNA fragment) at a time, NGS technologies can produce billions of short reads per experiment. With billions of sequenced DNA fragments, it is clear to see that NGS technologies are completely reliant on the availability of NGS tools to support them.

Read full article

How sequence analysis programs are better prepared for the threat of antimicrobial resistance.

Dr. Kirsten Miller-Duys 25/02/2022

Antimicrobial resistance (AMR) is an international public health emergency as identified by the WHO. If no action is taken, we could be spending an additional 1,2 trillion dollars per year on health by 2050 due to the impact of AMR. Much work has been done in the public health space to try and bring attention to this pandemic, however it remains an under recognised and poorly addressed threat.

Read full article

Benefits of online end-to-end bioinformatics solutions.

Dr Natasha Wood 18/02/2022

End-to-end bioinformatics solutions are software, such as sequence analysis programs, that turn laboratory-produced data into interpretable results. Instead of spending hours analysing each individual experimental dataset, results from routine laboratory tests can be translated to meaningful results simply and quickly by end-to-end bioinformatics solutions.

Read full article

Discovering the Omicron variant of SARS-CoV-2: a CTO’s perspective

Dr Imogen Wright 18/02/2022

There are few feelings more distressing to a software developer than receiving news of a totally unknown error experienced by an important customer. At Hyrax Biosciences, we’re always trying to get just a little bit better at what we do: to improve our software, tests, review processes and deployment frameworks. We want our users to be able to forget about their NGS data analysis, and concentrate on what they do best: generating data.

Read full article

How SARS-CoV-2 evolved to put Exatype centre stage.

Dr. Imogen Wright 07/02/2022

Friends have repeatedly asked me the same question over the course of my last two years at Hyrax Biosciences. The question begins with "what’s it like working on the pandemic?", which is usually swiftly followed by either "that must be so meaningful" or "that must be so hard".

Read full article

Analysis support for additional SARS-CoV-2 sequencing protocols

Dr. Kirsten Miller-Duys 29/07/2021

At Hyrax Biosciences we continue to support the surveillance efforts for SARS-COV-2, to be able to detect and monitor Variants of Concern (VoC) and Variants of Interest (VoI). Our software platform Exatype makes the data analysis for next generation sequencing (NGS) data a simple, automated step in the genotyping process.

Read full article

Your sequence data.
One solution.

Get in touch